News

PipelineReview.com17h
CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM
PLAINSBORO, NJ, USA I June 22, 2025 I Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial ...
PipelineReview.com16h
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions
BEIJING, China and BRIDGEWATER, NJ, USA I June 21, 2025 I Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced that the ...
PipelineReview.com17h
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
BASEL, Switzerland I June 23, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase I/II data on NXT007 in people with haemophilia A, ...
PipelineReview.com17h
Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
CAMBRIDGE, MA, USA; ROTTERDAM, The Netherlands and SHANGHAI, China I June 22, 2025 I Harbour BioMed (HKEX: 02142), a global biopharmaceutical company ...
PipelineReview.com2d
Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide
GRAND RAPIDS, MI, USA I June 20, 2025 I Cirius Therapeutics, Inc., a developer of innovative therapies for patients suffering from diseases caused by ...
PipelineReview.com2d
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – ...
PipelineReview.com2d
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
Pivotal Phase III SUNMO study demonstrated an 11.5 month median progression-free survival – three times longer than R-GemOx – ...
PipelineReview.com2d
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
AMSTERDAM, The Netherlands I June 20, 2025 I argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...
PipelineReview.com2d
CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children’s Health
HONG KONG, China I June 20, 2025 I Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening ...
PipelineReview.com3d
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
SAN DIEGO, CA, USA I June 20, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...
PipelineReview.com3d
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo ...
PipelineReview.com3d
Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation
With unmatched executional momentum and differentiated programs, Candid Therapeutics is defining a new future in immunology through its commitment to TCEs in autoimmune diseases. Additional trial ...